Alzheimer’s disease (AD) continues to rise in prevalence, placing substantial strain on patients, caregivers, and healthcare systems worldwide. Diagnostic innovation remains central to addressing this challenge—particularly in identifying the disease earlier, when therapeutic interventions may offer the greatest benefit.
For years, biomarker methods such as cerebrospinal fluid (CSF) analysis and positron emission tomography (PET) scans have supported the detection of amyloid pathology. Yet these approaches, while highly informative, can be invasive, less accessible, and operationally demanding.
In recent years, a meaningful paradigm shift has emerged with blood‑based biomarkers, especially phosphorylated tau (pTau) isoforms, including pTau181, as well as pTau217 and amyloid-beta 42. These biomarkers offer the potential for scalable, timely assessment of AD pathology through a routine blood draw.
The first FDA-approved blood test for diagnosing Alzheimer’s disease
Momentum has accelerated further with the U.S. Food and Drug Administration’s (FDA) recent clearance of the first pTau181 blood test intended to aid in the evaluation of Alzheimer’s-related pathology in adults with cognitive impairment, including use in primary care settings. Together with the earlier clearance of a plasma biomarker ratio test incorporating pTau217 and amyloid-beta42 for specialty care, the US now has multiple regulatory-approved blood-based biomarker options designed to support clinical assessment pathways.
Advances in regulatory-approved biomarkers, whether applied as standalone markers or in ratios, may increasingly support evaluation in both specialty and primary care. This shift could streamline referrals, reduce diagnostic delays, and make earlier assessment and diagnosis more accessible to patients experiencing cognitive concerns.
Alzheimer’s testing: Why CSF remains part of the solution
Despite the rapid progress in blood-based biomarkers, CSF and amyloid PET retain important, complementary roles. Current clinical guidelines continue to recommend CSF biomarkers and PET imaging to confirm amyloid pathology and to qualify symptomatic individuals for amyloid-targeting therapies in specialty settings.
Each modality offers distinct advantages, as well as limitations:
PET enables direct visualization and quantitation of amyloid deposition in the brain but faces accessibility challenges.
CSF provides a biochemical window into brain pathology with lower likelihood for protein degradation or peripheral interference compared with blood-based matrices. However, CSF collection requires a lumbar puncture—safe but often perceived by patients as more invasive—which can limit use for first-line, large-scale testing approaches.
Rather than competing with blood-based diagnostics, CSF testing often provides essential resolution in cases of indeterminate blood test results or when positive triage test findings require confirmatory evidence. CSF assays relying on a single diagnostic cutoff, without indeterminate zones, may help streamline clinical decision-making when confirmation is needed.
The path toward blood-based biomarkers adoption
As amyloid-targeting therapies become more widely available, laboratories and clinicians will face increasing demand for fluid biomarker testing.
Successful and responsible adoption of blood-based biomarkers requires several key considerations:
- Comprehensive validation or verification of biomarker performance in populations reflective of real-world practice.
- Greater understanding of each test's intended use, as well as its analytical and clinical characteristics.
- Recognition of how disease prevalence affects positive predictive value, particularly when transitioning from specialty care to primary care settings.
- Awareness of when confirmatory testing is needed, whether through CSF biomarker ratios or amyloid PET imaging.
- Careful attention to preanalytical variables, including specimen collection, storage, and transport, all of which influence test reliability and operational feasibility.
These considerations are critical not only for accurate interpretation but also for maintaining clinician and patient confidence as new biomarker technologies enter routine practice. Expert groups are actively developing guidance to support appropriate use of blood-based biomarkers in diagnostic workups.
As blood-based biomarkers become more accessible in primary care, increased focus will be placed on how these tests can support effective triage of patients with cognitive decline.
Continued collaboration, leadership, and innovation
Ongoing progress in neurology diagnostics relies on sustained collaboration among researchers, clinicians in both primary and specialty care settings, laboratories, and industry partners. Continued commitment in advancing AD biomarker research for different intended uses is essential, along with studies in populations reflective of real-world clinical practice. Availability of reference standards to ensure test accuracy are also key to ensuring robust, reproducible testing that supports clinical decision-making and improves patient outcomes.
A new era in Alzheimer’s diagnostics
The arrival of FDA-cleared blood-based AD biomarkers—including the recent pTau181 blood test—marks a pivotal moment in the evolution of Alzheimer’s diagnostics.
While CSF and PET will continue to play essential roles in confirming amyloid pathology, blood-based biomarkers offer a less invasive and highly scalable solution that may significantly expand access to timely assessment at earlier stages of disease.
With thoughtful adoption and continued innovation, these tools have the potential to transform diagnostic pathways and offer renewed hope for individuals affected by Alzheimer’s.
